TGF-β blocking combined with photothermal therapy promote tumor targeted migration and long-term antitumor activity of CAR-T cells
Source abstract
Abstract
TGF-β is widely existed in tumor microenvironment, taking part in tumorigenesis process including angiogenesis, cancer associated fibroblast (CAF) proliferation, and immunosuppression. It inhibited the activation, proliferation, migration and differentiation of T cells, in which way caused a limited therapeutic effects of chimeric antigen receptor T (CAR-T) towards solid tumor such as lymphoma. To targeted block TGF-β at tumor site, we take advantages of nano-techniques to deliver TGF-β inhibitors LY2157299 (LY) towards the tumor sites, in order to help achieve a improved and long-term functions of CAR-T towards lymphoma. Based on amphipathic hydroxyethyl starch-polycaprolactone (HES-PCL), LY and photosensitizer indocyanine green (ICG) were co-loaded in HES-PCL to achieve LY/ICG@HES-PCL nanoparticle. The enhanced function of CAR-T benefited from LY/ICG@HES-PCL were verified through lymphoma Raji cells in vitro and Nod scid gamma mice engrafted with the Raji cells in vivo. LY was targeted transported to tumor site and accelerated release by mild ICG photothermal. Chemokines CXCL9/10/11 at the tumor site relevant to CAR-T migration and chemokines receptor CXCR3 of CAR-T could be up-regulated by LY, thus facilitated the enhanced accumulation of CAR-T at lymphoma site. T effector memory cells differentiation could also be accelerated by LY/ICG@HES-PCL. Combined therapy of LY/ICG@HES-PCL and CAR-T achieved 2.4 times higher antitumor activity and 2.7 times higher relapse inhibiting rates than CAR-T alone within 15 days and 11 days, respectively. The results suggested that LY/ICG@HES-PCL facilitated the enhanced therapeutic index of CAR-T cells towards lymphoma simply and safely, it may be further potentiated applied for other solid tumors.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: CAR-T cell therapy research · Immunotherapy and Immune Responses · Immune Cell Function and Interaction
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (46)
Show source-provided references
1. Chimeric antigen receptor (CAR) T cells: lessons learned from targeting of CD19 in B-cell malignancies10.1007/s40265-017-0690-8 ↗
2. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients10.1172/JCI46110 ↗
3. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvages chemotherapy in refractory large B-cell lymphoma10.1182/bloodadvances.2020003848 ↗
4. Radionuclide-based molecular imaging allows CAR-T cellular visualization and therapeutic monitoring10.7150/thno.56989 ↗
5. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lyphomas: observations from the JULIET, ZUMA-1, and TRANScend trials10.1002/ajh.26301 ↗
6. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase І trial10.1158/1078-0432.CCR-16-1365 ↗
7. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology
8. Matrix crosslinking forces tumor progression by enhancing integrin signaling10.1016/j.cell.2009.10.027 ↗
9. Photothermal therapy promotes tumor infiltration and antitumor activity of CAR T cells
10. Emerging combination strategies with phototherapy in cancer nanomedicine10.1039/D0CS00215A ↗
11. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias10.1182/blood-2011-04-348540 ↗
12. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial10.1016/S0140-6736(14)61403-3 ↗
13. Chimeric antigen receptor T cells for sustained remissions in leukemia10.1056/NEJMoa1407222 ↗
14. Making sense of latent TGFbeta activation10.1242/jcs.00229 ↗
15. Stromal regulation of vessel stability by MMP14 and TGFbeta10.1242/dmm.003863 ↗
16. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation10.1016/j.ccr.2012.08.013 ↗
17. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance10.1016/j.ccr.2005.10.012 ↗
18. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression10.1038/nature05115 ↗
19. Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction10.4049/jimmunol.179.3.1979 ↗
20. Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis10.1053/jhep.2003.50194 ↗
21. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion10.1128/JVI.01177-06 ↗
22. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
23. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints10.1038/ncomms8458 ↗
24. TGF-beta inhibits IL-7-induced proliferation in memory but not naive human CD4+ T cells
25. Co-delivery nanoparticle to overcome metastasis promoted by insufficient chemotherapy10.1016/j.jconrel.2018.02.026 ↗
26. Genetically engineered hematopoietic stem cells deliver TGF-β inhibitor to enhance bone metastases immunotherapy
27. Self-assembled metallo-supramolecular nanoflowers for NIR/acidic-triggered multidrug release, long-term tumor retention and NIR-II fluorescence imaging-guided photo-chemotherapy10.1016/j.cej.2020.125882 ↗
28. Optical diagnostic imaging and therapy for thyroid cancer
29. NIR-light-controlled G-quadruplex hydrogel for synergistically enhancing photodynamic therapy via sustained delivery of metformin and catalase-like activity in breast cancer
30. Drug delivery of natural products through nanocarriers for effective breast cancer therapy: a comprehensive review of literature
31. Tumor-specific activatable biopolymer nanoparticles stabilized by hydroxyethyl starch prodrug for self-amplified cooperative cancer therapy10.7150/thno.67572 ↗
32. Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers10.1073/pnas.86.24.10108 ↗
33. Redox-sensitive hydroxyethyl starch-doxorubicin conjugate for tumor targeted drug delivery10.1021/acsami.6b11932 ↗
34. α-Amylase and redox-responsive nanoparticles for tumor-targeted drug delivery10.1021/acsami.7b04066 ↗
35. Recent advances in multifunctional nanomaterials for photothermal-enhanced Fenton-based chemodynamic tumor therapy
36. IR-780 dye loaded tumor targeting theranostic nanoparticles for NIR imaging and photothermal therapy10.1016/j.biomaterials.2013.05.071 ↗
37. The effect of molar mass and degree of hydroxyethylation on the controlled shielding and deshielding of hydroxyethyl starch-coated polyplexes10.1016/j.biomaterials.2012.12.025 ↗
38. Antitumor and antimetastatic activity of interleukin 12 against murine tumors10.1084/jem.178.4.1223 ↗
39. Selective addition of CXCR3(+)CCR4(-)CD4(+) Th1 cells enhances generation of cytotoxic T cells by dendritic cells in vitro10.3858/emm.2009.41.3.019 ↗
40. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation-A target for novel cancer therapy10.1016/j.ctrv.2017.11.007 ↗
41. TGF-β suppresses CD8 T cell expression of CXCR3 and tumor trafficking+10.1038/s41467-020-15404-8 ↗
42. The chemokine system in innate immunity
43. Construction of latent membrane protein 2A chimeric antigen receptor-T cells and their lethal effects on nasopharyngeal carcinoma cells
44. TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma10.1038/leu.2014.84 ↗
45. Nanocolloidosomes with selective drug release for active tumor-targeted imaging-guided photothermal/chemo combination therapy10.1021/acsami.7b14796 ↗
46. Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement10.1073/pnas.040570597 ↗